Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Sanofi
  6. News
  7. Summary
    SAN   FR0000120578

SANOFI

(SAN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sanofi : says its flu vaccine can be co-administered with Moderna's COVID-19 shot

10/20/2021 | 11:50am EST

Oct 20 (Reuters) - Sanofi SA's flu vaccine can be safely given along with Moderna Inc's COVID-19 vaccine, the French drugmaker said on Wednesday, citing study data.

The study supports the current recommendation by the U.S. Centers for Disease Control and Prevention (CDC) that flu and COVID-19 vaccines can be given simultaneously. The data was reported in slides set to be presented later to a panel of CDC advisers. (Reporting by Manas Mishra in Bengaluru; Editing by Shounak Dasgupta)


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
MODERNA, INC. -13.49% 265.33 Delayed Quote.153.98%
SANOFI 0.69% 84.35 Real-time Quote.7.18%
All news about SANOFI
12/06VACCINES INVESTOR EVENT : Sanofi reiterates confidence in strong growth outlook and showca..
PU
12/06Odyssey buys drugmaker BenevolentAI in Europe's biggest SPAC deal
RE
12/06SANOFI : EMA accepts regulatory submission for olipudase alfa, the first potential therapy..
PU
12/06Success For Sanofi And Rouse
AQ
12/03SANOFI : Deutsche Bank reaffirms its Sell rating
MD
12/02Vaccines Investor Event, Sanofi reiterates confidence in strong growth outlook and show..
AQ
12/02SANOFI : Receives a Buy rating from Kepler Cheuvreux
MD
12/02SANOFI : Receives a Buy rating from Credit Suisse
MD
12/02SANOFI : UBS maintains a Buy rating
MD
12/02SANOFI : Gets a Neutral rating from Barclays
MD
More news
Analyst Recommendations on SANOFI
More recommendations
Financials
Sales 2021 37 710 M 42 570 M 42 570 M
Net income 2021 6 202 M 7 002 M 7 002 M
Net Debt 2021 9 658 M 10 903 M 10 903 M
P/E ratio 2021 17,2x
Yield 2021 3,91%
Capitalization 106 B 119 B 120 B
EV / Sales 2021 3,06x
EV / Sales 2022 2,80x
Nbr of Employees 99 412
Free-Float 88,4%
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | MarketScreener
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 84,35 €
Average target price 107,07 €
Spread / Average Target 26,9%
EPS Revisions
Managers and Directors
Paul Hudson Chief Executive Officer & Director
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Serge Weinberg Chairman
John C. Reed EVP & Global Head-Research & Development
Nestle Frank Global Head-Immunology Therapeutic Research Area
Sector and Competitors
1st jan.Capi. (M$)
SANOFI7.18%119 412
JOHNSON & JOHNSON1.27%419 583
ROCHE HOLDING AG17.62%341 364
PFIZER, INC.44.09%304 610
NOVO NORDISK A/S64.51%244 010
ELI LILLY AND COMPANY47.55%222 641